Keytruda Cancer Drug's Cost, Patent Strategies, and Access Challenges Explored
21 hours agoBusiness
22LENS
2 SourcesMumbai, India
TBNthebalanced.news

Keytruda Cancer Drug's Cost, Patent Strategies, and Access Challenges Explored

Keytruda, an immunotherapy drug developed by Merck, has improved cancer treatment by enabling the immune system to target malignant cells. However, its high cost—ranging from Rs 1.5 lakh to 4 lakh per dose and extending over prolonged treatment—limits patient access. Investigations reveal Merck's use of patent extensions and regulatory strategies to delay cheaper alternatives, raising affordability concerns. In India, biosimilars are being developed to reduce costs, while issues like illicit vial refilling highlight challenges in drug distribution and accountability.

Political Bias
35%60%5%
Sentiment
52%
AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 17 Apr 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 2 sources
● Left 35%● Center 60%● Right 5%

The articles present perspectives focusing on pharmaceutical patent policies, drug pricing, and patient access without partisan framing. They include viewpoints from investigative journalists, medical experts, and industry practices, highlighting both innovation benefits and concerns over affordability and patent extensions. The coverage balances critique of corporate strategies with explanations of medical advances, reflecting a neutral stance on regulatory and healthcare issues.

Sentiment — Neutral (52/100)

The overall tone is mixed, acknowledging Keytruda's medical advancements and improved survival rates while expressing concern over high costs and ethical issues related to drug pricing and distribution. The investigative findings introduce a critical perspective on pharmaceutical practices, but expert explanations of the drug's mechanism provide a balanced, informative sentiment.

How 2 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
businessstandardWhat is Keytruda? How the cancer drug works and why it's in focusCenterNeutral
indianexpressSearch for cancer cure must not be hostage to Big PharmaLeftNeutral

Coverage timeline

indianexpress broke this story on 17 Apr, 01:50 am. Other outlets followed.

  1. 1
    indianexpress17 Apr, 01:50 am
    Search for cancer cure must not be hostage to Big Pharma
  2. 2
    businessstandard17 Apr, 10:38 am
    What is Keytruda? How the cancer drug works and why it's in focus

Lens Score breakdown

22/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Merck Co.Merck Co

Story context

Category
Business
Location
Mumbai, India
Sources analysed
2
Last analysed
17 Apr 2026
Key entities
PembrolizumabMerck & Co.PatentCancerImmunotherapyImmune systemIndiaPharmaceutical industryInternational Consortium of Investigative JournalistsTreatment of cancerMalignancyEthics